| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec693aef761bce2f70233e2540764f60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bce4435b0ef18937a102df500af607b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d48b8376633cc5b2ff19d72dbd7a1e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd39e399d54bfa3230f80bb1d12c9bb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_186eaa53f5d999ebed3a7a3bfbfa7a2f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate |
2012-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b042db993b4093fd729df0fe058a76e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ac9d1c2b924f4ac32218732e75ee2e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d37b35de56f2d920c308ea3188fdd3e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d6be64a6a175fcf9c19b8a74e552489 |
| publicationDate |
2017-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9682042-B2 |
| titleOfInvention |
MTB-C vaccine against asthma |
| abstract |
The invention relates to an agent for the treatment or prevention of an allergic condition, such as asthma, in a mammal. The agent comprises fragments of a Mycobacterium tuberculosis -complex (MTB-C) strain. These particular fragments may be from a virulent MTB-C strain and/or in the form of a liposome composition. The agent may include further components, such as a liposome-forming agent and/or particular proteins from the MTB-C strain. n A particular allergic response that may be treated by the agent of the invention is allergic asthma. A pharmaceutical composition comprising the agent is also provided. n Administration of the agent described herein significantly attenuates airway hyperresponsiveness, eosinophilia and lymphocytosis in the airways of sensitized animals. The effectiveness of the agent exceeds on all the evaluated parameters the commercial vaccine BCG Danish 1331 Strain. |
| priorityDate |
2012-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |